Is homozygosity for factor V Leiden a risk factor for myocardial infarction in young women who smoke? [2]

Thrombosis and Haemostasis

Volumn 93, Issue 3, 2005, Pages 616-617

  Patel, Raj K ^a   Ingram, Wendy ^a   MacCarthy, Philip ^a   Arya, Roopen ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TENECTEPLASE; TROPONIN T; WARFARIN;

ADULT; ANGINA PECTORIS; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CASE REPORT; CIGARETTE SMOKING; CLINICAL FEATURE; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; HEART CATHETERIZATION; HEART INFARCTION; HOMOZYGOSITY; HUMAN; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING HABIT; ST SEGMENT ELEVATION; TACHYCARDIA; THROMBOPHILIA;

EID: 15344338659     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616562     Document Type: Letter

References (14)

1. Rallidis LS, Belesi CI, Manioudaki HS, et al. Myocardial infarction under the age of 36: prevalence of thrombophilia disorders. Thromb Haemost 2003; 90: 272-8.
2. Rosendaal FR, Siscovick SM, Schwartz RK, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-21.
3. Rosendaal FR, Siscovick SM, Schwartz SM, et al. A common prothrombotic variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997; 90: 1747-50.
4. Siscovick DS, Schwartz SM, Rosendaal FR, et al. Thrombosis in the young: effect of atherosclerotic risk factors on the risk of myocardial infarction associated with prothrombotic factors. Thromb Haemost 1997; 78: 7-12.
5. Tanis BC, Bloemenkamp DG, van den Bosch MA, et al. Prothrombotic coagulation defects and cardiovascular risk factors in young women with acute myocardial infarction. Br J Haematol 2003; 122: 471-8.
6. Rees DC, Cox M, Clegg JB. World distribution of FV Leiden. Lancet 1995; 346: 1133-34
7. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993; 342: 1503-6.
8. van der Meer FJM, Koster T, Vandenbroucke JP, et al. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997; 78: 631-5.
9. Holm J, Hillarp, Zoller B, et al. Factor V Q506 (resistance to activated protein C) and prognosis after acute coronary syndrome. Thromb Haemost 1999; 81: 857-60.
10. Holm J, Zoller B, Svensson PJ, et al. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 1994; 344: 952-3.
11. Menge H, Faig HG, Lang A, et al. Homozygous form of factor V Leiden mutation as the cause of a myocardial infarction in patient with an unremarkable coronary vascular system?. Deutsche Medizinische Wochenschrift 2001; 126: 684-6.
12. Montaruli B, Voorberg J, Tamponi G, et al. Arterial and venous thrombosis in two Italian families with the factor V Arg506-Gln mutation. Eur J Haematol 1996; 57: 96-100.
13. Van Es RF, Jonker JJ, Verheugt FW, et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002; 360: 109-13
14. Hurlen M, Smith P, Amesen H, et al. Effect of warfarin, aspirin and the two combined, on mortality and thrombo-embolic morbidity after myocardial infarction: the WARIS-II (Warfarin-Aspirin Reinfarction Study) design. Scand Cardiovasc J 2000; 34: 168-71.